If virtual clinical trials had not quite taken off before coronavirus hit the world, they certainly are now. “It feels like every sponsor is coming to us and asking how much of their existing trials can be virtualized, or at least go partly remote,” said Greg Licholai, chief medical officer at PRA Health Sciences, a contract research organization. There is now a dramatic, urgent shift to embrace models that have been technically feasible for many months, even years, but which cultural and mind-set barriers have hitherto blocked. “The majority of trials will adjust to include more remote monitoring and potentially more remote data collection,” said Licholai.
The pandemic has shut down population movements and transport systems across large parts of the world, preventing many clinical trial...
